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Objectives The purpose of this systematic review and meta-analysis was to determine the efficacy and safety of fibrate
therapy in the chronic kidney disease (CKD) population.
Background Fibrate therapy produces modest cardiovascular benefits in people at elevated cardiovascular risk. There is lim-
ited evidence about the clinical benefits and safety of fibrate therapy in the CKD population.
Methods MEDLINE, EMBASE, and the Cochrane Library were systematically searched (1950 to January 2012) for prospec-
tive randomized controlled trials assessing the effects of fibrate therapy compared with placebo in people with
CKD or on kidney-related outcomes were included.
Results Ten studies including 16,869 participants were identified. In patients with mild-to-moderate CKD (estimated glo-
merular filtration rate [eGFR] 60 ml/min/1.73 m2), fibrates improved lipid profiles (lowered total cholesterol
[0.32 mmol/l, p  0.05] and triglyceride levels [0.56 mmol/l, p  0.03] but not low-density lipoprotein cho-
lesterol [0.01 mmol/l, p  0.83]; increased high-density lipoprotein cholesterol [0.06 mmol/l, p  0.001]). In
people with diabetes, fibrates reduced the risk of albuminuria progression (relative risk [RR]: 0.86; 95% confi-
dence interval [CI]: 0.76 to 0.98; p  0.02). Serum creatinine was elevated by fibrate therapy (33 mol/l,
p  0.001), calculated GFR was reduced (2.67 ml/min/1.73 m2, p  0.01) but there was no detectable
effect on the risk of end-stage kidney disease (RR: 0.85; 95% CI: 0.49 to 1.49; p  0.575). In patients with
eGFR of 30 to 59.9 ml/min/1.73 m2, fibrates reduced the risk of major cardiovascular events (RR: 0.70;
95% CI: 0.54 to 0.89; p  0.004) and cardiovascular death (RR: 0.60; 95% CI: 0.38 to 0.96; p  0.03) but
not all-cause mortality. There were no clear safety concerns specific to people with CKD but available data
were limited.
Conclusions Fibrates improve lipid profiles and prevent cardiovascular events in people with CKD. They reduce albuminuria
and reversibly increase serum creatinine but the effects on major kidney outcomes remain unknown. These
results suggest that fibrates have a place in reducing cardiovascular risk in people with mild-to-moderate CKD.
(J Am Coll Cardiol 2012;60:2061–71) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.049The burden of chronic kidney disease (CKD) is large and
growing, affecting 10% to 15% of the adult population
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Effects of Fibrates in Chronic Kidney Disease November 13, 2012:2061–71kidney deterioration including al-
buminuria or proteinuria (4) CKD
is associated with increased risk of
kidney failure and cardiovascular
events (5–11). While preventing
progressive kidney dysfunction is a
core aspect of managing these indi-
viduals, the risk of cardiovascular
disease is greatly elevated in people
with CKD and is the leading cause
of death in this population (12,13).
Treatments that can prevent 1 or
both of these adverse outcomes are
therefore key to improving the long-
term outcomes for this high-risk
group.
See page 2072
Accumulating data suggest that a range of interventions
that are effective at preventing cardiovascular disease in the
general population are likely to be similarly efficacious in
people with CKD. Recent evidence suggests that lipid
lowering (14), antiplatelet agents (15), and blood pressure
lowering (16,17) prevent cardiovascular events in CKD, and
the latter may also prevent progression of renal disease (18).
A meta-analysis of studies assessing the effects of fibrates
on cardiovascular events in the broader population has
reported overall benefit, with consistent evidence of greater
effects for subgroups with elevated triglyceride and/or de-
creased HDL levels (19). However, no adequately powered
outcome study of fibrate therapy has been reported to date
specifically in the CKD population.
While dyslipidemia is a risk factor for progressive kidney
disease (8,10,20,21) the acute elevation of creatinine caused
by fibrates (22) has resulted in concerns about the safety of
this therapy in the CKD population (23) and there have
been conflicting reports regarding the impact of fibrate
therapy on kidney function (24,25).
In this systematic review, we sought to synthesize the
available clinical trial evidence to better define any benefits
of fibrate therapy on kidney-related outcomes and on
cardiovascular events in people with CKD, as well as any
adverse effects.
Methods
Data sources and searches. We performed a systematic
review of the literature according to the PRISMA statement
for the conduct of meta-analyses of intervention studies.
Relevant studies were identified by searching the following
data sources: MEDLINE via Ovid (from 1950 to January
2012), EMBASE (from 1966 to January 2012), and the
Cochrane Library database (Cochrane Central Register of
Controlled Trials; no date restriction), using relevant text
Abbreviations
and Acronyms
CI  confidence interval
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
ESKD  end-stage kidney
disease
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
RR  relative riskwords and medical subject headings that included all spell- uings of fibrate, clofibrate, clofibric acid, bezafibrate, gemfibrozil,
enofibrate, procetofen, renal insufficiency, kidney failure, chronic
idney disease, albuminuria, serum creatinine, mortality, car-
iovascular disease, myocardial infarction, revascularization,
nd stroke. The search was limited to randomized controlled
rials but without language restriction. Reference lists from
dentified trials and review articles were manually scanned to
dentify any other relevant studies. The U.S. government’s
linical Trials database was also searched for randomized
rials that were registered as completed but not yet
ublished.
tudy selection. The literature search, data extraction, and
uality assessment were conducted independently by 2
uthors (M.J. and B.Z.) using a standardized approach. All
ompleted randomized controlled trials assessing the effects of
fibrate compared to placebo that reported 1 or more of the
rimary or secondary outcomes were eligible for inclusion.
ata extraction and quality assessment. Published re-
orts were obtained for each trial and standard information
as extracted into a spreadsheet. The data sought included
aseline patient characteristics (age, sex, history of diabetes,
reatinine, renal function, lipid levels, and body mass index),
brate used, dose of drug, follow-up duration, change in
ipid levels, outcome events, and adverse events. Study
uality was judged by the proper conduct of randomization,
oncealment of treatment allocation, similarity of treatment
roups at baseline, the provision of a description of the
ligibility criteria, completeness of follow-up, and use of
ntention-to-treat analysis, and was quantified using the
adad score (26). Any disagreement in abstracted data was
djudicated by a third reviewer (V.P.). Attempts were made
o contact individual authors of included studies to seek
dditional data wherever possible. A total of 6 authors were
ontacted, and additional data were received from 1 author.
To investigate the effects of fibrates on major clinical
utcomes, additional unpublished summary level data on a
ubgroup (n  399) of the VA-HIT (Veterans Affairs
igh-Density Lipoprotein Intervention Trial) was sought
nd obtained.
utcomes. We collected data on lipid profiles (total cho-
esterol, triglyceride, low-density lipoprotein [LDL], and
igh-density lipoprotein [HDL]), albuminuria, serum cre-
tinine and renal function changes, end-stage kidney disease
ESKD), major clinical outcomes (cardiovascular events,
ardiovascular death, stroke, all-cause mortality), and ad-
erse events.
ata synthesis and analysis. Individual study relative risks
RRs) and 95% confidence intervals (CIs) were calculated
rom event numbers extracted from each trial before data
ooling. In calculating risk ratios, the total number of
atients randomized in each group was used as the denom-
nator. For continuous parameters, weighted mean differ-
nces were calculated using end-of-trial mean values, their
orresponding standard deviations and treatment arm size.
ummary estimates of relative risk ratios were obtained
sing a random effects model. The percentage of variability
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November 13, 2012:2061–71 Effects of Fibrates in Chronic Kidney Diseaseacross studies attributable to heterogeneity beyond chance
was estimated using the I2 statistic (27). Potential publica-
ion bias was assessed using the Egger test and represented
raphically using Begg funnel plots of the natural log of the
R versus its standard error (28).
A 2-sided p value 0.05 was considered statistically
ignificant. Statistical analyses were performed with Stata,
ersion 9.2 (StataCorp, College Station, Texas) and RevMan,
ersion 5.1 (Cochrane IMS, Copenhagen, Denmark).
esults
earch results and characteristics of included studies.
he literature search yielded 2,142 articles, of which 26
ere reviewed in full text (Fig. 1). Of these, 8 randomized
ontrolled trials published in 10 articles met the inclusion
riteria, including a total of 16,869 patients (24,25,29–36).
f the identified articles, 3 were post-hoc analyses
25,33,36) and 2 were subsequent pre-specified analyses
24,34) of randomized controlled trials in people with a
revious history of coronary heart disease or type 2 diabetes.
hree studies reported the effect of fibrate therapy on lipid
rofiles in patients with mild to moderate kidney disease
Figure 1 Identification of Eligible Studies
The flowchart depicts the process in which the eligible studies to be included in thefined as estimated glomerular filtration rate (eGFR) 60
l/min/1.73 m2 (31,32,36). Three studies reported the
effect of fibrate therapy on serum creatinine levels
(29,30,32). Three studies reported sufficient data on renal
function changes by treatment allocation for pooling to be
possible (25,31,32). Two studies reported major cardiovas-
cular events and all-cause mortality according to baseline
eGFR (34,36). The majority of other studies identified by
our search did not examine fibrate therapy, examined
fibrates in combination with other drug classes, compared
fibrates to other drug classes, were not original investiga-
tions, or were duplicates of reports already identified.
Table 1 summarizes the characteristics of the included
studies. The trials had a sample size that ranged from 24 to
9,795 participants with follow-up periods that ranged from
3 months to 5.1 years. Of the 8 trials identified, 2 were
single-center studies, 5 were multicenter studies, and 1 was
unspecified. Studies were conducted in some or all of the
United States, Canada, Europe, and Oceania. Two trials
assessed the effects of gemfibrozil (25,31), 2 assessed beza-
fibrate (29,30), and 4 assessed fenofibrate (24,32,33,35).
The trial results were published between 1992 and 2011.
ematic review and meta-analysis were identified.e syst
Characteristics of Studies Reporting the Effects of Fibrates on Kidney-Related OutcomesTable 1 Characteristics of Studies Reporting the Effects of Fibrates on Kidney-Related Outcomes
First Author (Ref. #) Inclusion Criteria Treatment Group Placebo
Design
(Country of Origin)
Duration of
Follow-Up
(Mean) n
Mean
Age
(yrs)
Male
(%)
Diabetes
(%)
Baseline
Cholesterol
(mmol/l)
Mean Baseline
SCr
(mol/l)
Mean Baseline
eGFR
(ml/min/1.73 m2)
Barbir et al. (29) Chol 6.5 mmol/l,
TG 2.8 mmol/l
Bezafibrate Fish oil Randomized single
center (United
Kingdom)
3 months 87 53 90 0 7.3 140 4 NR
Bruce et al. (30) Diabetic nephropathy, mild renal
impairment, dyslipidemia (chol
6.2 mmol/l, TG 2.3 mmol/l,
HDL 0.9 mmol/l)
Bezafibrate (400 mg
daily)
Placebo Randomized
unspecified
number of
centers (New
Zealand)
6 months 24 58 NR 100 7.2 108  27 in
bezafibrate
102  17 in
placebo
91
Samuelsson et al. (31) Non-nephrotic, nondiabetic,
“moderately advanced CRI”
Gemfibrozil (300–
900 mg daily)
Dietary
counseling
Randomized single
center (Sweden)
1 yr 57 51 75 0 6.30 187 CrCl 35.5
Levin et al. (32) CrCl 20–74 ml/min1.73 m2,
TG 2.23 mmol/l or
LDL/HDL chol ratio 5;
age 20–70 yrs
Fenofibrate (67–201
mg daily)
Dietary
counseling
Randomized
multicenter
(Canada)
6 months 28 57 82 54 6.36 186  72 in
fenofibrate
190  96 in
placebo
CrCl 46.5
Tonelli et al. VA-HIT
post-hoc subgroup (36)
Original trial: age 74 yrs, history
of CHD, absence of serious
coexisting conditions,
HDL 1.0 mmol/l, LDL 3.6
mmol/l, and TG 3.4 mmol/l. In
this publication, mild CRI
defined as CrCl 60–75 ml/min
and moderate CRI as 30–59.9
ml/min
Gemfibrozil (1,200
mg daily)
Placebo Randomized
multicenter
(United States)
5.1 yrs
(median)
1,046* 67 100 28 4.5 NR MDRD 62.1;
CrCl 61.5
Tonelli et al. VA-HIT
post-hoc subgroup
analysis (25)
Original trial: Age 74 yrs, history
of CHD, absence of serious
coexisting conditions,
HDL 1.0 mmol/l, LDL 3.6
mmol/l, and triglyceride 3.4
mmol/l. In this publication,
moderate CRI defined as MDRD
GFR 30–59.9 ml/min/1/73 m2
Gemfibrozil (1,200
mg daily)
Placebo Randomized
multicenter
(United States)
5.1 yrs
(median)
399† 67 100 30 4.35 NR MDRD 52.2;
CrCl 59.7
Ansquer et al. DAIS
post-hoc subgroup
analysis (33)
Original trial: Age 40–65 yrs,
type 2 DM, lipid profile total
cholesterol-to-HDL ratio of
4 plus either LDL 3.5–4.5
mmol/l, trig 5.2 mmol/l, or TG
1.7–5.2 mmol/l and LDL 4.5
mmol/l
Fenofibrate (200 mg
daily)
Placebo Randomized
multicenter
(Canada,
Finland, France,
and Sweden)
3.3 yrs 314‡ 57 76 100 5.54 88  18
(fenofibrate
arm); 80  9
(placebo arm)
NR
Continued on next page
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November 13, 2012:2061–71 Effects of Fibrates in Chronic Kidney DiseaseThe mean age of the study participants ranged between 51
and 67 years. Males represented the majority of the participants
in all but 1 of the studies identified (1 did not report the
proportion of sex), ranging from 63% to 100% (29,31–33,35–38).
Four studies were undertaken exclusively among patients with
diabetes (24,30,33,35). Five studies had specific lipid profile
requirements for trial entry (25,29,30,32,33).
In multicenter studies, 2 studies reported the use of a
central laboratory for the measurement of albuminuria
and/or serum creatinine (32,35), 2 reported the use of 2 core
laboratories (33,37), and 1 reported using local laboratories
located in the area of the participating sites (38).
The risk of bias was assessed using key indicators of trial
quality (Online Table 1). Earlier smaller studies provided
few details about the process of randomization, concealment
of allocation, and the use of intention-to-treat analysis
techniques. Double blinding was reported to have been used
in 4 studies (32,35,37,38), with 1 reporting that renal
outcomes such as serum creatinine measurements were
performed by individuals blinded to study treatment (38).
Overall, 4 trials had a Jadad score of 4 (24,25,32,35), 1
scored 3 (33), 2 scored 2 (29,31), and 1 scored 1 (30). In
sensitivity analyses that excluded the studies with a Jadad
score of3, the overall point estimates for the key outcomes
including lipid profiles and serum creatinine were similar to
the primary analysis.
Effects of fibrate therapy. LIPID PROFILES. In patients
with mild-to-moderate kidney disease, fibrate therapy sig-
nificantly lowered total cholesterol (0.32 mmol/l; 95% CI:
0.64 to 0.00 mmol/l; p  0.05) and triglyceride levels
0.56 mmol/l; 95% CI: 1.06 to 0.06 mmol/l; p 
.03), but had no effect on LDL levels (0.01 mmol/l; 95%
I: 0.11 to 0.09; p  0.83). There was evidence of
oderate (I2  48%, p  0.15) and significant (I2  72%,
 0.03) heterogeneity for the outcomes of total choles-
terol and triglyceride levels, respectively. Fibrate therapy
significantly increased HDL levels (0.06 mmol/l; 95% CI:
0.04 to 0.08 mmol/l; p  0.001) with no evidence of
heterogeneity of effects (I2  0.0%, p  0.50) (Fig. 2).
emfibrozil, compared with fenofibrate, tended to be more
fficacious in improving triglyceride levels but not total
holesterol, LDL, or HDL levels.
ALBUMINURIA. Three trials, including 14,385 participants
and 3,883 events, reported data regarding the progression of
albuminuria (24,35). In type 2 diabetes patients, fibrate
therapy reduced the risk of albuminuria progression (relative
risk [RR]: 0.86; 95% CI: 0.76 to 0.98; p  0.02), with
moderate evidence of heterogeneity (I2  63%, p for
heterogeneity  0.06) (Fig. 3). Two trials, including 2,152
participants and 919 events, reported data regarding the
regression of albuminuria (24,33) with fibrate therapy sig-
nificantly increasing the likelihood of albuminuria regres-
sion (RR: 1.19; 95% CI: 1.08 to 1.31; p  0.0005) (Fig. 3).
SERUM CREATININE AND RENAL FUNCTION. Serum creati-
nine was significantly elevated with fibrate therapy (32.6Co T
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Effects of Fibrates in Chronic Kidney Disease November 13, 2012:2061–71mol/l; 95% CI: 21.6 to 43.7 mol/l; p  0.001), and
eGFR was reduced (2.67 ml/min/1.73 m2; 95% CI:
4.81 to 0.54 ml/min/1.73 m2) with no evidence of
eterogeneity (I2  0.0%, p  0.50 for both serum
creatinine and eGFR changes) (Fig. 4).
Figure 2 Effect of Fibrates on Lipid Profiles
Effect of fibrates (gemfibrozil and fenofibrate) compared with placebo on total cholesterol,
CI  confidence interval.
Figure 3 Effect of Fibrates on Albuminuria
Effect of fibrates on the progression and regression of albuminuria. CI  confidenOne study measured kidney function in a subset of the
total population after study medication had been ceased. A
reduction in eGFR was noted during study treatment, but
this was reversed off therapy where eGFR levels were higher
in the group that had been treated with long-term fenofi-
rides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL).
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November 13, 2012:2061–71 Effects of Fibrates in Chronic Kidney Diseasebrate (total eGFR loss 5.8 vs. 9.9 ml/min/1.73 m2, p 
.001) (24).
END-STAGE KIDNEY DISEASE. Two studies, with follow-up
urations of 1 and 5 years, including 9,852 participants
mong whom 50 events were observed reporting on the
ffect of fibrates on ESKD (24,31) and found no clear effect
Fig. 5) (RR: 0.85; 95% CI: 0.49 to 1.49; p  0.575).
MAJOR CARDIOVASCULAR OUTCOMES. Two studies that
included 12,326 participants over a follow-up duration of 5
years reported the effect on major cardiovascular events (n
1,970), cardiovascular death (n  377), stroke (n  467),
and all-cause mortality (n  1,097) according to baseline
enal function (25,34). Patients with moderate renal impair-
Figure 4 Effect of Fibrates on Serum Creatinine and Kidney Fun
Effect of fibrates on kidney-related outcomes including serum creatinine and kidne
glomerular filtration rate (GFR) based on plasma or renal clearance of 51Cr-EDTA; L
GFR using the MDRD (Modification of Diet in Renal Disease) study equation. CI 
Figure 5 Effect of Fibrates on End-Stage Kidney Disease
Effect of fibrates on progression to end-stage kidney disease. CI  confidence inteent fibrate therapy produced a 30% (p  0.004) reduction
n the risk of major cardiovascular events with no evidence
f heterogeneity (I2  0.0%, p  0.72) and a 40% (p 
0.032) reduction in the risk of cardiovascular death with no
evidence of heterogeneity (I2  0.0%, p  0.44) (Fig. 6).
Fibrate therapy had no clear effect on cardiovascular death
in patients with eGFR 60 ml/min/1.73 m2 (p for heter-
ogeneity  0.066). Fibrate therapy had no overall effect on
the risk of stroke or all-cause mortality (Fig. 6).
ADVERSE EVENTS. There were several adverse outcomes re-
ported although only by a limited number of trials. One study
reported mild gastrointestinal symptoms in the gemfibrozil
group (6 of 28) (31) with another reporting epigastric pain in
tion measured by the glomerular filtration rate. Samuelsson et al. (31) measured
t al. (32) measured creatinine clearance; Tonelli et al. (38) calculated estimated
ence interval.ction
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reported no differences in depression, nondermatological ma-
lignancy, or skin cancer (25). Nausea, leg cramps, headaches,
tonsillitis, and gouty arthritis were also reported (29). One
study conducted in people with type 2 diabetes, reported a
small increase in the risk of pancreatitis (23 [0.5%] vs. 40
[0.8%]; p 0.031) and pulmonary embolism (32 [0.7%] vs. 53
1%]; p  0.022). However, these results were not specific for
he CKD subgroup but were for the entire trial (37).
Due to limited availability of data and differences in
eporting methods, it was not possible to quantitatively
ombine adverse events to produce a summative result.
PUBLICATION BIAS. Formal statistical testing to assess for
Figure 6 Effect of Fibrates on Major Clinical Outcomes in Patie
Effect of fibrates on cardiovascular disease and all-cause mortality according to estim
CI  confidence interval; CKD  chronic kidney disease.ublication bias was not possible due to the limited avail- Sbility of data and different reporting methods employed by
he studies. However, examination of funnel plots of out-
omes with 3 or more studies did not suggest the presence
f publication bias (Online Fig. 1).
iscussion
his quantitative review has 2 major findings. First, the
vailable data suggests that fibrate therapy reduces the risk
f cardiovascular events in patients with CKD including
rotection against cardiovascular death. The effects in peo-
le with CKD appeared at least as large as the effects in
eople with normal kidney function, although formal sta-
istical testing to confirm this was limited by sample size.
ith CKD
omerular filtration rate (eGFR) category.nts W
ated glecond, the available data demonstrates that fibrate therapy
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hoc analysis of the FIELD (Fenofibrate Intervention and
Event Lowering in Diabetes) study suggested that this is
likely to be reversible and that it may mask an underlying
benefit for kidney function. Further support for this is
provided by the observed reductions in proteinuria with
fenofibrate. There were no clear safety concerns specific to
the CKD population identified, but available data were
limited. While a large outcome trial conducted specifically
in this population is required to more clearly define these
effects, the available data support the overall safety and
potential benefits of this class of agents (39,40).
The graded association between CKD stage and cardio-
vascular risk highlights the urgent need to identify beneficial
therapies for this population (41). Fibric acid derivatives are
effective in improving lipid profiles and reducing the risk of
cardiovascular events with evidence showing greater efficacy
of fibrates in people with baseline hypertriglyceridemia
(19,42). The higher levels of triglycerides and the lower
HDL levels in the CKD population therefore provide a
strong rationale for expecting greater magnitudes of benefit
in CKD. Other mechanisms specific to CKD populations
could also explain our findings. For example, levels of
kidney function and albuminuria have been shown to be
strong and independent predictors of cardiovascular risk,
and it is possible that the observed beneficial effects on
albuminuria (and perhaps the putative benefits for kidney
function suggested in the FIELD study) could also lead to
long-term cardiovascular benefit. These results suggest net
benefit if fibrates are used more widely in people with
kidney disease. However, there are currently no data avail-
able for individuals with more severe levels of kidney
dysfunction (eGFR30 ml/min/1.73 m2), and the available
data come from subgroup analyses of trials in broader
populations. Of note, the recent SHARP (Study of Heart
and Renal Protection) trial clearly demonstrated that statin-
based LDL lowering prevents cardiovascular events in CKD
patients, particularly those with early disease (14). Few of
the participants in the trials included in the current review
were treated with statins, so that the effects of combined
treatment remain uncertain. The ACCORD (Action to
Control Cardiovascular Risk in Diabetes) trial participants
all received statins but the effects on cardiovascular out-
comes in the CKD population have not been reported. This
would be of great interest. Nonetheless, a new trial specif-
ically designed and powered to define the potential protec-
tive effects of these agents in people with a range of levels of
kidney dysfunction treated with statins would therefore be
valuable.
As well as uncertainty about efficacy, the use of fibrates in
patients with kidney disease has been limited due to safety
concerns related to the documented increases in serum
creatinine (43,44), associations with increased hospitaliza-
tion and nephrologist consultations (45), and with uncer-
tainty about the implications for longer-term renal out-
comes. The National Kidney Foundation and the NationalLipid Association have both made recommendations for the
cautious use of fibrates in patients with CKD based on this
perceived risk (40). Drug-induced elevations in serum cre-
atinine have been reported in those with mild to moderate
renal failure (46) and renal transplant recipients (47,48),
however, the mechanism behind this elevation is unclear. A
potential mechanism explaining the change in serum creat-
inine with fibrate therapy is interference in the generation of
vasodilatory prostaglandins by fibrates due to the activation
of peroxisome proliferator–activated receptors (49) causing a
change in renal blood flow and consequently increasing
serum creatinine and reducing GFR. Hottelart and col-
leagues reported that serum creatinine was elevated with
fenofibrate but without evidence of a reduction in GFR as
assessed by inulin clearances (46). The authors proposed
that creatinine production may be increased with fibrate
therapy but that GFR remains unchanged. These potential
explanations have supported the view that the drug-induced
elevations in serum creatinine does not reflect a true
deterioration of renal function and many studies reporting
this rise as a transient phenomenon have further strength-
ened this view (44,50). Indeed, the reduction in eGFR may
not be paralleled by a reduction in directly measured GFR
using inulin (24,37). Post-trial studies of the FIELD and
ACCORD trials have explored the drug-induced serum
creatinine elevation and have improved our knowledge
regarding the safety of fibrate therapy. A post-hoc analysis
from the FIELD study reported that plasma creatinine
levels in a cohort of 661 “substudy washout participants” 8
weeks after withdrawal from study treatment were signifi-
cantly lower in participants who had received fenofibrate
compared to placebo (p  0.001) suggesting longer-term
renoprotective effects despite the initially elevated serum
creatinine (24). Similarly, reversibility in acute increases in
creatinine has been described amongst participants in the
ACCORD study (50). Taken together, these results suggest
that the acute changes in creatinine with fibrate therapy do
not translate into adverse effects on major clinical renal
outcomes, and indeed suggest the possibility of long-term
renal benefit. This provides another strong rationale for an
outcome trial specifically conducted in people with CKD.
Adverse events reporting was inconsistent, limiting the
conclusions that can be drawn, however, no specific adverse
outcomes were noted to be specifically elevated in CKD.
This systematic review has comprehensively searched the
literature for available evidence regarding the effects of fibrate
therapy in patients with CKD. It highlights the relative paucity
of data in the field, particularly in patients with advanced
kidney disease (eGFR30 ml/min/1.73 m2). In addition, the
risk of bias assessments of the individual trials have shown
that some of the studies were of suboptimal quality in terms
of providing adequate descriptions of allocation conceal-
ment and lacking the use of double-blinding. Adequate
reporting of quality indicators is a validated measure of the
quality of trial conduct, strongly related to the internal
validity of randomized controlled trials (51). Therefore,
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The lack of double-blinding may leave open the possibility
of information and ascertainment bias, which may particu-
larly be an issue when assessing subjective outcomes such as
renal outcomes (52). These biases could lead to overestima-
tion of benefit or underestimation of harm.
Study limitations. This review has limitations primarily
resulting from the scarcity of current trial evidence. Al-
though we were able to obtain new unpublished data to
assess the effects of fibrate therapy on major clinical out-
comes, only 2 trials (both of which were conducted in
people with type 2 diabetes) reported outcomes by baseline
level of kidney function. Insufficient data were available to
allow separate analysis of effects in people with and without
diabetes. The majority of the studies identified were small
and lacked power to detect clinically important effects of
fibrates, particularly on advanced renal outcomes such as
ESKD. None of the studies we identified included people
with advanced CKD (eGFR 30 ml/min/1.73 m2) and
herefore our results cannot be extrapolated to these indi-
iduals. One study reported the use of fish oil as the placebo,
hich may be a potential confounder as fish oil is known to
odify lipid profiles, however, the inclusion of this study
oes not substantially impact on the overall outcome of this
eview as the study did not contribute to the results on lipid
rofile or cardiovascular outcomes. In addition, differences
n reporting methods restricted the pooling of data. Per-
orming analyses based on published summary level data
imited the capacity to fully explore the effects of fibrate
herapy in CKD patients and there remains significant
otential for an overview based on individual patient data to
rovide more insight into the effects of fibrates based on
KD stage.
onclusions
ibrate therapy improves lipid profiles and prevents cardio-
ascular events in people with kidney disease. Albuminuria
s also improved in patients with type 2 diabetes mellitus
nd while serum creatinine is increased there is no evidence
hat this translates into long-term adverse effects on kidney
unction in any population studied. Patients with advanced
KD represent a high-risk population and our findings
uggest that assessing the benefits of fibrates in people with
dvanced CKD should be a high priority. In the meantime,
hese results suggest that fibrates could be used more
roadly in patients with mild to moderate CKD to prevent
ardiovascular disease.
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